This week’s issue covers developments shaping access to HIV prevention and the future of US biomedical research, including new pathways to accelerate access to lenacapavir for HIV PrEP, calls for ...
An analysis by Jirair Ratevosian of the Duke Global Health Institute looked comprehensively at AI-related abstracts, key themes from use cases, and emerging trends at AIDS 2026. His review shows the ...
The annual US Conference on HIV/AIDS will take place in Anaheim, California, from September 17-20, 2026. The conference is the nation’s largest convener of community, workforce and frontline service ...
We believe that the struggle to end the AIDS epidemic depends on delivering effective HIV prevention, which in turn depends on resilient health systems incorporating policies and practices that ...
The US National Institutes of Health (NIH) signs a 10-year agreement that could move significant NIAID research funding to the Department of Defense, as NIAID separately proposes a major restructuring ...
Preparing people affected by HIV to preserve and expand research The US HIV Cure Academy connects people affected by HIV with leading researchers to explore the latest HIV cure strategies and equip ...
New York City, September 12, 2024 – AVAC welcomes the groundbreaking results of the PURPOSE 2 HIV prevention study of twice-yearly injectable lenacapavir for PrEP among 3,200 cisgender men, ...
AVAC and Access Bridge applaud Merck’s announcement today that it has granted seven direct licenses to generic manufacturers to produce their investigational monthly pill for HIV prevention, known as ...
In support of Dr. Anthony Fauci, AVAC submitted a letter to the Committee on Homeland Security and Governmental Affairs ahead of a Congressional hearing focused on the origins of COVID-19. This letter ...
New York City, June 20, 2024 – AVAC welcomes the groundbreaking results of the PURPOSE 1 HIV prevention study among adolescent girls and young women in South Africa and Uganda. Preliminary safety and ...
The stop-work orders have disrupted USAID-supported HIV prevention research, halting critical investigations in vaccine and next-generation PrEP strategies. The abrupt suspension of these trials also ...
Significant challenges persist in the wake of cuts to PEPFAR funding and programs, as the ripple effects continue to be felt across the field and organizations grapple with how to maintain services ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results